Bluebird bio's exit from Europe last year signals rough seas ahead for gene therapy developers, who are trying to gain market access for their products. Evidently, bluebird bio couldn’t strike deals with European payers for its EMA-approved gene therapies, Zynteglo (beti-cel) and Skysona (eli-cel).
Subscribe to:
Post Comments (Atom)
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
-
Robert Connely of Pega says patching legacy systems will give way to true health IT modernization, a security breakthrough will lead artific...
No comments:
Post a Comment